Blue Horseshoe Stocks: PIRS Review & More

Pieris Pharmaceuticals Inc. PIRS – Review

Of all the types of plays we search for, bottom watch plays can require the most amount of patience as compared to other quick-strike ideas that we formulate. We highlighted PIRS as such back in mid-February, and over the past quarter, the stock has produced some very favorable results in two distinct runs.

When we initially signaled our interest in this stock, or shortly thereafter, it was trading for as little as 2.83 and over the course of the next two months, it gradually made its way to 4.00 (+41%). After a pullback down near its original level at 2.81 halfway through last month, the stock has begun to run once again. This time it has reached all new highs, with the stock changing hands for as much as 4.68/share on Friday. That second push allowed us to see an overall increase of 67%

We wouldn’t be at all surprised to have to come back to PIRS once again in the near future. In addition to the company’s joint clinical venture with pharma super giant AstraZeneca, the stock itself has recently received analyst upgrades that could just be the beginning of PIRS’s next leg-up.


Xalles Holdings, Inc. XALL

We are also looking at the incredible momentum recently built up by XALL, which has been assisted by the resurgence of Bitcoin here in 2019, which began in January in the mid-$3000 range, and has persisted to the present time to the current highs near $8700.

The company also recently decreased its public float by around 50%, making it that much easier for the stock to move. We’ll be interested to continue to monitor its progress, especially if the latest Bitcoin boom continues to persist as it has in recent months.


Extended Watchlist:
DRRX, CBLK, BLNK, CTRV, MOSY, SNSS, NVCN, ATVI, LAHO(>>News Alert)

Blue Horseshoe Stocks: Form-4 Alert & More

Snap, Inc. SNAP – Update

Even as the markets got crushed yet again yesterday despite it appearing as if the worst of the downturn was over, SNAP still managed to produce gains in our updated options trading targets.

It was in our premarket report yesterday that we were updating readers on the previous idea we had with the SNAP $16-17.50 Calls, which made moves ranging from 335-700% the day prior.

The stock had risen by such a large margin that we rolled up our potential strike prices to the $21-22.50 levels, and we got very nice activity out of half of those calls to keep our success with the SNAP options chain rolling.

The $21 Calls ran from .04-.32, for a fantastic 700% rip, while the 21.50’s made a 400% from .03-.15.
________

Fresh Options Idea:

Provided the SPY holds above 259.50 we’ll be interested in the SPY Weekly $260.50-262 Calls*

*Please do not attempt to trade weekly options on a Friday unless you are an expert level trader with disposable funds.



LendingClub Corp. LC

With turmoil in the markets persisting, this is a time when we want to stick to our technicals, and look for stocks that are currently boasting the type of chart setups we routinely scan for, and LC currently matches the profile.

The stock has come down to double-bottom with a gap to fill to the upside, as you can see on the included snapshot. We feel that over the next few weeks, LC could be in line for a solid recovery.

In addition to the stock itself, we’re going to radar a pair of options contracts to track over a more extended period of time, with the LC 03/16 $3.50 & $4 Calls.


Seattle Genetics, Inc. SGEN – Form-4 Alert

While we’re on the subject of bottom-plays, we’ve got SGEN hitting our scanner this morning. We’ll include a chart snapshot of this one as well, so you can see what we find so attractive about it. We’ve got a triple-bottom formation happening with the stock coming down to he $50-range, and a recent track record of the type of volatility we’re after.

To sweeten the pot, a major Form-4 buy came in the last week at $52, to the tune of $200M (View EDGAR Filing) in addition to a multi-program immuno-oncology collaboration with Pieris Pharmaceuticals announced this morning.

We’re going to track the SGEN 03-16 $50 Calls in the days and weeks ahead.


Extended Watchlist:
PIRS, AVIN, CTRL, CFMS, CNET, INPX

Blue Horseshoe Stocks: DCTH Review & More

Delcath Systems, Inc. DCTH
We flagged DCTH in Friday’s premarket reportas a prime bottom-bounce candidate that could be in line for a serious rebound, and even despite the markets as a whole taking a gut punch, it ended up being a great single-session play, and the NASDAQ’s top gainer.

From an early low of .0501 the stock surged as high as .0845, which works out to an intraday rise of 69% and it occurred on more than ten times the 30-day average volume, with DCTH logging its second-highest daily volume of all time.

We’d say our timing was extremely fortuitous on this rebound play, and with the kind price action and liquidity that we witnessed Friday, we’ll definitely be interested to see how the action unfolds to kick off this new trading week.


TrovaGene, Inc. TROV

We wanted to make mention of TROV this morning after noticing a cherry of a PR buzzing over the newswires. The company announced an agreement to provide tests and services for pharma giant AstraZeneca.

Whenever we see one of these smaller pharma company’s have joint news with a big player in the sector, we always want to pay attention to the stock. A perfect example of this is Pieris Pharmaceuticals, Inc. PIRS, which we signaled back on May 4th when that company also had news tying it to none other than AstraZeneca. What followed was a 55% run lasting nearly a month that took it from 3.26 the following day to a high of 5.06 last Monday, the 31st.

On the chance that TROV experiences a similar bullish push on the heels of its own AstraZeneca announcement, we’re going to be sure to have this one on watch in coming sessions.


Ascena Retail Group, Inc. ASNA

We’re also taking notice of a nice technical setup on ASNA, which owns the Lane Bryant retail brand among others, and was another of the NASDAQ’s top gainers of the day on Friday.

The activity came in the wake of a rather disappointing earnings release in terms of financials, but investors clearly responded well to the company outlook moving forward.

As you can see on the included snapshot, the stock picked up speed in its recent ascent off of a bottom, and began to fill a gap on the chart to the upside. We also have a number of other indicators pointing to a possible continued uptrend, so we’ll afford this stock a slot on our watchlist.


Extended Watchlist:
XBIT, DXTR, RWLK, ABIL, ADHD, ENRJ